NBIX News and Press, Neurocrine Biosciences Inc. From 06/13/22

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 PR Newswire - Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents...

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43 rd Annual Global Heal...

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala PR Newswire SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of n...

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022 PR Newswire SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today pr...

QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan) are now commercialized by Idorisa, and Johnson & Johnson is distributing Ponvory (Ponesimod). The Swiss and Canadian health authorities are supposed to give their feedback on QUVIVIQ very soon. The stock price has been repeatedly...

Neurocrine Biosciences (NASDAQ:NBIX) plans to repurchase ~$179.4M aggregate principal amount of its existing 2.25% Convertible Senior Notes due 2024. It entered into separate, privately negotiated transactions with certain holders of the notes to repurchase ~$179.4M of notes at an aggregate r...

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022 PR Newswire SAN DIEGO , May 23, 2022 /PRNewswire/ -- Ne...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Neurocrine Biosciences' (NASDAQ:NBIX) valbenazine to treat Huntington disease (HD). The company said treatment of chorea associated with HD is within the scope of the orphan drug designation. HD is a rare, gen...

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has ...

The decision by Pfizer (NYSE:PFE) to acquire the commercial-stage biopharma company, Biohaven Pharmaceutical (BHVN) for nearly $12 billion has revived the beaten-down biotech space on Tuesday. SPDR S&P Biotech ETF (XBI) is trading higher after three sessions of declines to record the...